1. Lymphoma in Pediatrics 23rd Nov 2018
Prof. Mohammad Faranoush

2. Rituximab in childhood Non-Hodgkins lymphoma
IR.MABSC.EDU

3. Back ground
Since the late 1960s, treatment outcomes for pediatric patients with non-Hodgkin lymphoma have steadily improved.
Even for patients with advanced disease, event-free survival rates are now 65-90%.
IR.MABSC.EDU

4. Back ground
The mainstay of conventional therapy is multiagent chemotherapy tailored to the histologic subtype and the clinical stage of disease.
In certain individuals with non-Hodgkin lymphoma, surgical resection and radiation therapy are also key components of definitive treatment.
Newer therapies that target immunologic and biologic aspects of the lymphoma are still under development but beginning to appear in the clinical arena.
IR.MABSC.EDU

5. Classification
According to the National Cancer Institute (NCI) formulation, most childhood non-Hodgkin lymphomas can be classified as one of the following types:
Lymphoblastic lymphomas
Small noncleaved cell lymphomas (SNCCLs) - Burkitt lymphomas and non-Burkitt lymphomas (Burkittlike lymphomas)
Large cell lymphomas (LCLs)
IR.MABSC.EDU
IR.MABSC.EDU

6. IR.MABSC.EDU

7. Disease progression
Most malignancies arise as disease localized in the organ or tissue of origin.
They may then secondarily spread by means of local extension or distant metastases.
In contrast, non-Hodgkin lymphoma is best regarded as a systemic disease, because of the unique anatomy of the lymphoid system and because of the physiology of lymphoid cells, which tend to migrate whether they are normal or malignant.
The role of lymphoma stem cells in the genesis and maintenance of B-cell lymphomas remains speculative
IR.MABSC.EDU

8. Table 3. Demographic characteristics of patients in PHIS-assembled cohort compared to the National Cancer Institute’s SEER program.
Citrin R, Horowitz JP, Reilly AF, Li Y, Huang YS, et al. (2017) Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. PLOS ONE 12(10): e
IR.MABSC.EDU

9. Prognosis
The overall prognosis for children with non-Hodgkin lymphoma has steadily improved. Period analysis of SEER data for children under 15 years showed that 5- and 10-year survival increased, respectively, from 76.6% and 73.0% in to 87.7% and 86.9% in The projected 10-year survival rate for children diagnosed in was 90.6%
IR.MABSC.EDU

10. prognosis
Among patients with non-Hodgkin lymphoma, the major determinants of prognosis are histology and disease stage.
The presence or absence of particular molecular markers (eg, anaplastic lymphoma kinase (ALK) and/or CD56 in anaplastic large cell lymphoma [LCL]) has additional prognostic significance
IR.MABSC.EDU

11. Approach Considerations
Progress in the treatment of children and adolescents with NHL parallels that of childhood acute lymphoblastic leukemia.
IR.MABSC.EDU

12. Treatment Surgery Chemotherapy Radotherapy SCT Relapsed disease
IR.MABSC.EDU

13. Monoclonal Ab Rituximab (anti-CD20 antibody)
Pembrolizumab (monoclonal antibody that binds the programmed cell death-1 protein (PD-1) ligands PD-L1 and PL2)
Obinutuzumab (GA101)
Veltuzumab (IMMU-106)
Blinatumomab (AMG103) bi-specific CD19/CD3T-cell engager
Ibrutinib
IR.MABSC.EDU

14. Indication
IR.MABSC.EDU

15. Rituximab therapy in newly diagnosed pediatric NHL
DLBCL and BL is the expression of the protein CD20. CD20 is an ideal target for antibody therapy
Some study in pediatric patients with CD20– positive NHL hasnot yet to demonstrate an improvement in EFS or OS with the addition of frontline rituximab therapy
IR.MABSC.EDU

16. Rituximab
The intergroup Phase III trial, ANHL1131 (NCT ), which was designed to test the efficacy of frontline rituximab therapy in pediatric patients with B-cell NHL opened in 2010
Some improvement in OS
up to 20% of patients who receive rituximab therapy will have prolonged hypogammaglobulinemia and impaired immune function
IR.MABSC.EDU

17. IR.MABSC.EDU

25. Summary
Treatments for NHL may start to mimic those for pediatric acute leukemias, where minimal residual disease monitoring enables the identification of those patients who will require either escalation or subtraction of therapy.
Novel frontline trials in pediatric patients with NHL using the several potentially useful agents may provide improvement of EFS while diminishing toxicity from standard chemotherapy.
IR.MABSC.EDU

26. Doing now what patients need next